BetaCure (2014-2018)

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology


Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over fundtioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem expecially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.)

The project is coordinated by the Radboud university medical center in Nijmengen, Netherlands

The consortium consists of 17 partners from the Netherlands, Switzerland, Germany, United Kingdom, Finland, France and Austria.

For further information on the project, please refer to the video of Prof. Gotthardt, coordinator of the BetaCure EU-Project, on youtube.


This project has received funding from the European Union´s Seventh Framework Programme for research, technological development and demonstration under grant agreement no. 602812.